Healthcare Services

Global Gastric Cancer Diagnostic Procedure Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Gastric Cancer Diagnostic Procedure Market Between 2026 And 2030?

The gastric cancer diagnostic procedure market size has shown significant expansion in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.65 billion in 2026, registering a compound annual growth rate (CAGR) of 7.4%. This historical growth can be linked to the utilization of endoscopy in gastric diagnosis, the implementation of biopsy procedures, the accessibility of imaging tests, existing hospital-based diagnostic infrastructure, and the establishment of pathology labs.

The gastric cancer diagnostic procedure market is projected to experience substantial expansion over the upcoming years. This market is set to reach $2.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the forecast period include the advancement of liquid biopsy techniques, the broadening of molecular diagnostics, an increased need for early detection, enhanced automation in diagnostic processes, and AI-enabled imaging analysis. Key trends anticipated during the forecast period encompass the increasing application of endoscopic diagnostic techniques, a surge in the adoption of molecular and genetic testing, a heightened call for early-stage cancer detection, the proliferation of non-invasive diagnostic procedures, and the incorporation of sophisticated imaging technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12038&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Gastric Cancer Diagnostic Procedure Market?

The growing increase in smoking is anticipated to boost the expansion of the gastric cancer diagnostic procedure market moving forward. Smoking is defined as the act of breathing in and out the smoke produced by burning tobacco or similar substances. Gastric cancer diagnostic procedures are crucial for individuals with a history of smoking or those at risk of smoking-related cancers, providing benefits such as early detection and identification of precancerous lesions, assisting in the development of personalized and tailored treatment plans, facilitating better communication and coordination, and offering a comprehensive assessment of the gastric mucosa and surrounding tissues. For instance, in July 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that tobacco kills more than 8 million people each year, including 1.3 million non-smokers exposed to second-hand smoke. Therefore, the increasing prevalence of smoking is a key factor driving the growth of the gastric cancer diagnostic procedure market.

Which Market Segments Are Examined In The Gastric Cancer Diagnostic Procedure Market Study?

The gastric cancer diagnostic procedure market covered in this report is segmented –

1) By Procedure Type: Endoscopic Procedure, Biopsy, Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics, Immunoassays, Other Procedure Types

2) By Symptom Type: Symptomatic, Asymptomatic

3) By Offering Type: Instruments, Reagents And Consumables, Services

4) By Body Fluid Type: Blood, Urine, Saliva, Stomach Juice, Tissue, Other Body Fluid

5) By Disease Indication: Early Gastric Cancer, Advanced Gastric Cancer

Subsegments:

1) By Endoscopic Procedure: Upper Endoscopy (EGD), Endoscopic Ultrasound (EUS)

2) By Biopsy: Endoscopic Biopsy, Fine Needle Aspiration (FNA) Biopsy

3) By Tissue Tests: Histopathology, Immunohistochemistry

4) By Lab Tests: Blood Tests, Tumor Markers

5) By In-Vitro Diagnostic Tests: Genetic Testing, Molecular Profiling

6) By Imaging Tests: Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan

7) By Molecular Diagnostics: PCR Testing, Next-Generation Sequencing (NGS)

8) By Multiplexing Molecular Diagnostics: Multiplex PCR, Microarray Analysis

9) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

10) By Other Procedure Types: Breath Tests, Liquid Biopsies

Which Trends Are Impacting The Growth Of The Gastric Cancer Diagnostic Procedure Market?

Major companies operating in the gastric cancer diagnostic procedure market are prioritizing technological advancements, such as dual cell-free and exosomal miRNA liquid biopsy assays, to gain a competitive advantage. These assays work by measuring small noncoding RNAs released both freely in the bloodstream and contained within tumor-derived exosomes, allowing for highly sensitive and specific detection of gastric cancer from a simple blood sample. For instance, in December 2024, Cizzle Bio, a U.S.-based biotechnology company, launched its DEX G2 blood test. This test combines cell-free and exosomal miRNAs to achieve approximately 95% sensitivity and 97% specificity, requiring only a standard blood draw instead of an invasive endoscopy. This innovation offers the promise of earlier diagnosis and broader screening reach, although widespread adoption could be constrained by regulatory approval timelines and the necessity for real-world validation.

Who Are The Primary Competitors In The Gastric Cancer Diagnostic Procedure Market?

Major companies operating in the gastric cancer diagnostic procedure market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Myriad Genetics Inc., Foundation Medicine Inc., Biocept Inc., Illumina Inc., Roche Diagnostics, QIAGEN N V, Bio-Rad Laboratories Inc., Siemens Healthineers, Danaher Corporation, Becton Dickinson, bioMérieux SA, PerkinElmer Inc., NeoGenomics Laboratories, Guardant Health Inc., Natera Inc., Caris Molecular Diagnostics, Adaptive Biotechnologies Corp, 10x Genomics Inc

Read the full gastric cancer diagnostic procedure market report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

What Are The Leading Geographic Regions In The Gastric Cancer Diagnostic Procedure Market?

North America was the largest region in the gastric cancer diagnostics procedure market in 2025. The regions covered in the gastric cancer diagnostic procedure market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastric Cancer Diagnostic Procedure Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12038&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Diagnostic Procedure Market 2026, By The Business Research Company

Gastric Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Ulcers Global Market Report

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795